Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. (Q44398270)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 July 2011

Language	Label	Description	Also known as
English	Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.	scientific article published on 19 July 2011

Statements

scholarly article

1 reference

Europe PubMed Central

2 December 2017

Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. (English)

1 reference

Europe PubMed Central

2 December 2017

Anders Fomsgaard

object named as

Anders Fomsgaard

1

0 references

object named as

Peter Andersen

8

0 references

author name string

Ingrid Karlsson

2

1 reference

Europe PubMed Central

2 December 2017

Gregers Gram

3

1 reference

Europe PubMed Central

2 December 2017

Christian Schou

4

1 reference

Europe PubMed Central

2 December 2017

Sheila Tang

5

1 reference

Europe PubMed Central

2 December 2017

Peter Bang

6

1 reference

Europe PubMed Central

2 December 2017

Ingrid Kromann

7

1 reference

Europe PubMed Central

2 December 2017

Lars Vibe Andreasen

9

1 reference

Europe PubMed Central

2 December 2017

language of work or name

0 references

publication date

19 July 2011

1 reference

Europe PubMed Central

2 December 2017

1 reference

Europe PubMed Central

2 December 2017

29

1 reference

Europe PubMed Central

2 December 2017

40

1 reference

Europe PubMed Central

2 December 2017

7067-7074

1 reference

Europe PubMed Central

2 December 2017

The immune response during acute HIV-1 infection: clues for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Are we on course for reporting on the Millennium Development Goals in 2015?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Therapeutic vaccines for chronic infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Sequence conservation of subdominant HLA-A2-binding CTL epitopes in HIV-1 clinical isolates and CD8+ T-lymphocyte cross-recognition may explain the immune reaction in infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

A comparative study of cationic liposome and niosome-based adjuvant systems for protein subunit vaccines: characterisation, environmental scanning electron microscopy and immunisation studies in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Cationic liposomes as vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Liposome-based cationic adjuvant formulations (CAF): past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Broadly immunogenic HLA class I supertype-restricted elite CTL epitopes recognized in a diverse population infected with different HIV-1 subtypes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Early induction and maintenance of Env-specific T-helper cells following human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

CD4+ T cells support cytotoxic T lymphocyte priming by controlling lymph node input.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

HLA class I supertypes: a revised and updated classification

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Response definition criteria for ELISPOT assays revisited

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

The utility of the minipig as an animal model in regulatory toxicology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Development of a HIV-1 lipopeptide antigen pulsed therapeutic dendritic cell vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Control of viremia and prevention of AIDS following immunotherapy of SIV-infected macaques with peptide-pulsed blood

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Cross-reactive CD8+ T cell epitopes identified in US adolescent minorities

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

An HLA-A11-specific motif in nonamer peptides derived from viral and cellular proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.07.025

7 January 2021

Identifiers

10.1016/J.VACCINE.2011.07.025

1 reference

Europe PubMed Central

2 December 2017

1 reference

Europe PubMed Central

2 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44398270&oldid=1369008360"